• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结直肠癌患者血清中可溶性血管内皮生长因子受体1的浓度。

Soluble VEGFR1 concentration in the serum of patients with colorectal cancer.

作者信息

Abbasi Oranus, Mashayekhi Farhad, Mirzajani Ebrahim, Fakhriyeh Asl Saba, Mahmoudi Touraj, Saeedi Saedi Hamid

机构信息

Department of Cell and Molecular Biology, Pardis International, University of Guilan, Rasht, Iran.

出版信息

Surg Today. 2015 Feb;45(2):215-20. doi: 10.1007/s00595-014-0886-4. Epub 2014 Mar 28.

DOI:10.1007/s00595-014-0886-4
PMID:24676933
Abstract

PURPOSE

VEGFR is involved in complex biological processes, including inflammation and cancer development, progression and metastasis. Many proteins, including VEGFR, are proteolytically released from the surface of cells by a process known as ectodomain shedding. The aim of this study was to assess the expression of soluble VEGFR1 (sVEGFR1) in the serum of patients with colorectal cancer (CRC).

METHODS

Sixty-two serum samples from healthy controls and 88 samples from patients with different stages of CRC were included in this study. The total protein concentration (TPC) was measured using a Bio-Rad protein assay, and the expression and concentration of sVEGFR1 was determined by a Western blot analysis and enzyme-linked immunosorbent assay, respectively.

RESULTS

No significant difference in the serum TPC of patients with and without CRC was seen. The relative s-VEGFR1 expression and concentration of sVEGFR1 in the serum of patients with CRC were significantly increased compared to those in controls (P < 0.001).

CONCLUSIONS

The results of this study suggest that VEGFR1 shedding may provide a reliable and practical indicator of the malignant potential, tumor progression and overall tumor burden. The findings also suggest that sVEGFR1 might be involved in the pathophysiology of CRC, and the detection of serum sVEGFR1 may be useful in classifying CRC.

摘要

目的

血管内皮生长因子受体(VEGFR)参与包括炎症和癌症发生、发展及转移在内的复杂生物学过程。许多蛋白质,包括VEGFR,可通过一种称为胞外域脱落的过程从细胞表面被蛋白水解性释放。本研究的目的是评估可溶性VEGFR1(sVEGFR1)在结直肠癌(CRC)患者血清中的表达。

方法

本研究纳入了62份来自健康对照者的血清样本和88份来自不同分期CRC患者的样本。使用Bio-Rad蛋白质测定法测量总蛋白浓度(TPC),并分别通过蛋白质印迹分析和酶联免疫吸附测定法测定sVEGFR1的表达和浓度。

结果

CRC患者和非CRC患者的血清TPC未见显著差异。与对照组相比,CRC患者血清中s-VEGFR1的相对表达和sVEGFR1的浓度显著升高(P < 0.001)。

结论

本研究结果表明,VEGFR1脱落可能为恶性潜能、肿瘤进展和总体肿瘤负荷提供可靠且实用的指标。研究结果还表明,sVEGFR1可能参与CRC的病理生理学过程,血清sVEGFR1的检测可能有助于CRC的分类。

相似文献

1
Soluble VEGFR1 concentration in the serum of patients with colorectal cancer.结直肠癌患者血清中可溶性血管内皮生长因子受体1的浓度。
Surg Today. 2015 Feb;45(2):215-20. doi: 10.1007/s00595-014-0886-4. Epub 2014 Mar 28.
2
Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis.可溶性血管内皮生长因子受体1在结直肠癌中的过表达:与进展和预后的关系。
Cancer Sci. 2007 Mar;98(3):405-10. doi: 10.1111/j.1349-7006.2007.00402.x.
3
Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.乳腺癌患者血清血管内皮生长因子(VEGF)及其可溶性受体sVEGFR1与血清游离DNA的比较。
Cytokine. 2008 Oct;44(1):65-9. doi: 10.1016/j.cyto.2008.06.008. Epub 2008 Aug 8.
4
Soluble VEGFR1 (sVEGFR1) as a novel marker of amyotrophic lateral sclerosis (ALS) in the North Indian ALS patients.可溶性血管内皮生长因子受体 1(sVEGFR1)作为北印度肌萎缩侧索硬化症(ALS)患者的新型标志物。
Eur J Neurol. 2012 May;19(5):788-92. doi: 10.1111/j.1468-1331.2011.03548.x. Epub 2011 Oct 7.
5
Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period.微创结肠切除术与术后早期血浆可溶性血管内皮生长因子受体1(sVEGFR1)水平短暂升高及可溶性血管内皮生长因子受体2(sVEGFR2)水平降低有关。
Surg Endosc. 2009 Apr;23(4):694-9. doi: 10.1007/s00464-008-0323-0. Epub 2009 Jan 28.
6
Interleukin-4 and granulocyte-macrophage colony-stimulating factor mediates the upregulation of soluble vascular endothelial growth factor receptor-1 in RAW264.7 cells-a process in which p38 mitogen-activated protein kinase signaling has an important role.白细胞介素-4和粒细胞-巨噬细胞集落刺激因子介导RAW264.7细胞中可溶性血管内皮生长因子受体-1的上调——这一过程中p38丝裂原活化蛋白激酶信号传导起重要作用。
J Microbiol Immunol Infect. 2016 Jun;49(3):344-51. doi: 10.1016/j.jmii.2014.06.008. Epub 2014 Aug 12.
7
Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.原发性人类结直肠癌中血管内皮生长因子受体1、2、3的异质性
Anticancer Res. 2016 Jun;36(6):2683-96.
8
Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery.围手术期使用沙格司亭(重组人粒细胞-巨噬细胞集落刺激因子)可使接受微创手术的结肠癌患者体内可溶性血管内皮生长因子受体1水平升高。
Eur J Surg Oncol. 2007 Dec;33(10):1169-76. doi: 10.1016/j.ejso.2007.03.014. Epub 2007 May 18.
9
The Association between Vascular Endothelial Growth Factor-related Factors with Severity of Multiple Sclerosis.血管内皮生长因子相关因子与多发性硬化严重程度之间的关联
Iran J Allergy Asthma Immunol. 2016 Jun;15(3):204-11.
10
Profiling of cytokines, chemokines and other soluble proteins as a potential biomarker in colorectal cancer and polyps.分析细胞因子、趋化因子和其他可溶性蛋白作为结直肠癌和息肉的潜在生物标志物。
Cytokine. 2017 Nov;99:35-42. doi: 10.1016/j.cyto.2017.06.015. Epub 2017 Jul 6.

引用本文的文献

1
Tumor-suppressive role of the gene in colorectal cancer.该基因在结直肠癌中的肿瘤抑制作用。
iScience. 2023 Mar 23;26(4):106478. doi: 10.1016/j.isci.2023.106478. eCollection 2023 Apr 21.
2
Performance of DNA Methylation on the Molecular Pathogenesis of in Gastric Cancer; targeted therapy approach.DNA甲基化在胃癌分子发病机制中的作用;靶向治疗方法。
J Pharmacopuncture. 2022 Jun 30;25(2):88-100. doi: 10.3831/KPI.2022.25.2.88.
3
Advances in studies of tyrosine kinase inhibitors and their acquired resistance.酪氨酸激酶抑制剂及其获得性耐药的研究进展。

本文引用的文献

1
The role of VEGF and its receptors in the etiology of early pregnancy loss.血管内皮生长因子及其受体在早期妊娠丢失病因中的作用。
Gynecol Endocrinol. 2014 Feb;30(2):153-6. doi: 10.3109/09513590.2013.864272. Epub 2013 Dec 4.
2
Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.评估乳腺癌女性患者血管内皮生长因子(VEGF)及可溶性受体sVEGFR - 1和sVEGFR - 2的临床实用性。
Ann Agric Environ Med. 2013;20(2):293-7.
3
Associated expression of α2,3sialylated type 2 chain structures with lymph node metastasis in distal colorectal cancer.
Mol Cancer. 2018 Feb 19;17(1):36. doi: 10.1186/s12943-018-0801-5.
4
Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer.血清代谢物GTA-446的下调作为早期检测结直肠癌的一种新型潜在标志物。
Br J Cancer. 2017 Jul 11;117(2):227-232. doi: 10.1038/bjc.2017.163. Epub 2017 Jun 20.
5
H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer.H19非编码RNA是一种独立的预后因素,可调节结直肠癌中关键的Rb-E2F和CDK8-β-连环蛋白信号通路。
EBioMedicine. 2016 Nov;13:113-124. doi: 10.1016/j.ebiom.2016.10.026. Epub 2016 Oct 19.
6
The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab.VEGFA、FLT1和KDR表达联合在结肠癌患者预后及预测贝伐单抗反应中的意义
Onco Targets Ther. 2015 Apr 15;8:835-43. doi: 10.2147/OTT.S80518. eCollection 2015.
α2,3 唾液酸化的 II 型链结构与远端结直肠癌淋巴结转移的相关性表达。
Surg Today. 2013 Feb;43(2):155-62. doi: 10.1007/s00595-012-0141-9. Epub 2012 Mar 8.
4
Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer.可溶性 VEGFR-1 在癌症抗血管生成治疗中的潜在作用。
Expert Rev Anticancer Ther. 2011 Apr;11(4):541-9. doi: 10.1586/era.10.171.
5
Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment.可溶性血管内皮生长因子受体-1 和 -2 通过募集壁细胞促进血管成熟。
FASEB J. 2010 Oct;24(10):3782-95. doi: 10.1096/fj.09-149070. Epub 2010 May 19.
6
The molecular therapy of colorectal cancer.结直肠癌的分子治疗。
Mol Aspects Med. 2010 Apr;31(2):171-8. doi: 10.1016/j.mam.2010.02.005. Epub 2010 Feb 19.
7
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.贝伐单抗与厄洛替尼联合用于晚期肝细胞癌患者的II期试验。
J Clin Oncol. 2009 Feb 20;27(6):843-50. doi: 10.1200/JCO.2008.18.3301. Epub 2009 Jan 12.
8
Cancer incidence and mortality in Iran.伊朗的癌症发病率和死亡率。
Ann Oncol. 2009 Mar;20(3):556-63. doi: 10.1093/annonc/mdn642. Epub 2008 Dec 10.
9
High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer.高水平的血管内皮生长因子及其受体(血管内皮生长因子受体-1、血管内皮生长因子受体-2、神经纤毛蛋白-1)与乳腺癌预后较差相关。
Hum Pathol. 2008 Dec;39(12):1835-43. doi: 10.1016/j.humpath.2008.06.004. Epub 2008 Aug 20.
10
Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.乳腺癌患者血清血管内皮生长因子(VEGF)及其可溶性受体sVEGFR1与血清游离DNA的比较。
Cytokine. 2008 Oct;44(1):65-9. doi: 10.1016/j.cyto.2008.06.008. Epub 2008 Aug 8.